Literature DB >> 24715529

Bioactivity of albumins bound to silver nanoparticles.

Jessy Mariam1, S Sivakami, D C Kothari, P M Dongre.   

Abstract

The last decade has witnessed a tremendous rise in the proposed applications of nanomaterials in the field of medicine due to their very attractive physiochemical properties and novel actions such as the ability to reach previously inaccessible targets such as brain. However biological activity of functional molecules bound to nanoparticles and its physiological consequences is still unclear and hence this area requires immediate attention. The functional properties of Human Serum Albumin (HSA) and Bovine Serum Albumin (BSA) bound to silver nanoparticles (~60 nm) have been studied under physiological environment. Esterase activity, binding of drugs (warfarin and ibuprofen), antioxidant activity and copper binding by albumins was evaluated. The catalytic efficiencies of HSA and BSA diminished upon binding to silver nanoparticles. Perturbation in binding of warfarin and ibuprofen, loss of free sulphydryls, antioxidant activity and enhancement of copper binding were observed in albumins bound to nanoparticles. These alterations in functional activity of nanoparticle bound albumins which will have important consequences should be taken into consideration while using nanoparticles for diagnostic and therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24715529     DOI: 10.1007/s10930-014-9553-2

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  52 in total

1.  Chemical modification of low-density lipoprotein enhances the number of binding sites for divalent cations.

Authors:  G Pifat; J Brnjas-Kraljević; G Jürgens; C M Herak-Kramberger; J N Herak
Journal:  Chem Phys Lipids       Date:  1992-12       Impact factor: 3.329

2.  The influence of surface composition of nanoparticles on their interactions with serum albumin.

Authors:  Lennart Treuel; Marcelina Malissek; Julia Susanne Gebauer; Reinhard Zellner
Journal:  Chemphyschem       Date:  2010-10-04       Impact factor: 3.102

3.  Nanobiotechnology: nanoparticle coronas take shape.

Authors:  Marco P Monopoli; Francesca Baldelli Bombelli; Kenneth A Dawson
Journal:  Nat Nanotechnol       Date:  2011-01       Impact factor: 39.213

4.  In vitro stereoselective degradation of carprofen glucuronide by human serum albumin. Characterization of sites and reactive amino acids.

Authors:  H Georges; N Presle; T Buronfosse; S Fournel-Gigleux; P Netter; J Magdalou; F Lapicque
Journal:  Chirality       Date:  2000-02       Impact factor: 2.437

5.  Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles.

Authors:  Tommy Cedervall; Iseult Lynch; Stina Lindman; Tord Berggård; Eva Thulin; Hanna Nilsson; Kenneth A Dawson; Sara Linse
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-31       Impact factor: 11.205

Review 6.  The antioxidant properties of serum albumin.

Authors:  Marjolaine Roche; Philippe Rondeau; Nihar Ranjan Singh; Evelyne Tarnus; Emmanuel Bourdon
Journal:  FEBS Lett       Date:  2008-05-12       Impact factor: 4.124

7.  Copper-binding properties of bovine serum albumin and its amino-terminal peptide fragment.

Authors:  T Peters; F A Blumenstock
Journal:  J Biol Chem       Date:  1967-04-10       Impact factor: 5.157

8.  Binding of Cu(II) to non-prosthetic sites in ceruloplasmin and bovine serum albumin.

Authors:  A Zgirski; E Frieden
Journal:  J Inorg Biochem       Date:  1990-06       Impact factor: 4.155

9.  Protein binding modulates the cellular uptake of silver nanoparticles into human cells: implications for in vitro to in vivo extrapolations?

Authors:  Nancy A Monteiro-Riviere; Meghan E Samberg; Steven J Oldenburg; Jim E Riviere
Journal:  Toxicol Lett       Date:  2013-05-06       Impact factor: 4.372

10.  Multi-metal binding site of serum albumin.

Authors:  W Bal; J Christodoulou; P J Sadler; A Tucker
Journal:  J Inorg Biochem       Date:  1998-04       Impact factor: 4.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.